60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)

Authors :: Fabien Zoulim
Céline Dorival
Dominique Larrey
Pierre-Henri Bernard
Jérôme Gournay
Ghassan Riachi
Laurent Alric
Valérie Canva
Didier Samuel
Fabrice Carrat
Hélène Fontaine
M. Bourlière
J.-J. Raabe
Jean-Pierre Bronowicki
Sophie Metivier
Yoann Barthe
J.-M. Pawlotsky
V. de Ledinghen
Christophe Hézode
Thierry Poynard
Stanislas Pol
Source :: Journal of Hepatology. 58:S27
Publication Year :: 2013
Publisher :: Elsevier BV, 2013.

Subjects :: chemistry.chemical_compound
Non responders
medicine.medical_specialty
Hepatology
chemistry
business.industry
Boceprevir
Internal medicine
medicine
business
Gastroenterology
Telaprevir
medicine.drug

Full Text Access

Tools